TRI-MILI
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TRI-MILI (TRI-MILI).
TRI-MILI is a combination of norethindrone (a progestin) and ethinyl estradiol (an estrogen). Norethindrone suppresses gonadotropin release, inhibiting ovulation. Ethinyl estradiol stabilizes the endometrium and potentiates the progestational effects.
| Metabolism | Norethindrone is metabolized via reduction and sulfate/glucuronide conjugation; CYP3A4 is involved. Ethinyl estradiol is primarily metabolized by CYP3A4 and undergoes conjugation with sulfate and glucuronide. |
| Excretion | Renal excretion of unchanged drug accounts for 60-80% of elimination; biliary/fecal excretion accounts for 15-25%; remainder metabolized. |
| Half-life | Terminal elimination half-life is 6-9 hours in adults with normal renal function, allowing twice-daily dosing; prolonged in renal impairment. |
| Protein binding | Approximately 85-90% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Vd is 1.5-2.5 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Oral bioavailability is 70-90% due to first-pass metabolism; intravenous bioavailability is 100%. |
| Onset of Action | Oral: 30-60 minutes; Intravenous: within 5 minutes. |
| Duration of Action | Oral: 8-12 hours; Intravenous: 6-8 hours; clinical effects persist for dosing interval. |
For mild-to-moderate hypertension: 1 tablet (containing triamterene 50 mg and hydrochlorothiazide 25 mg) orally once daily. May increase to 2 tablets daily if needed. Maximum dose: 4 tablets daily.
| Dosage form | TABLET |
| Renal impairment | Contraindicated if CrCl <30 mL/min. For CrCl 30-50 mL/min: reduce dose to maximum 1 tablet daily; monitor serum potassium frequently. |
| Liver impairment | Child-Pugh Class A: no adjustment needed. Child-Pugh Class B: initiate at half the usual dose and titrate cautiously. Child-Pugh Class C: contraindicated. |
| Pediatric use | Safety and efficacy not established in children <18 years; use not recommended. |
| Geriatric use | Start at lowest possible dose (e.g., 0.5 tablet daily) due to increased risk of electrolyte imbalances and hypotension; monitor renal function and serum potassium closely. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for TRI-MILI (TRI-MILI).
| Breastfeeding | Tri-Mili passes into breast milk in small amounts; estimated relative infant dose 1-5% of maternal weight-adjusted dose. M/P ratio: ethinyl estradiol ~0.04-0.6, norethindrone ~0.3-2.2. Combination hormonal contraceptives may reduce milk production, especially in early lactation. Use caution; consider progestin-only alternatives if breastfeeding is established. |
| Teratogenic Risk | Tri-Mili (ethinyl estradiol/norethindrone) is contraindicated in pregnancy. First trimester exposure: meta-analyses show no major increased risk of birth defects, but case-control studies suggest a possible small increased risk of cardiovascular malformations and hypospadias. Second and third trimester exposure: androgenic effects on female fetuses (labial fusion, clitoromegaly) and possible estrogenic effects on male fetuses (penile hypoplasia). Use in pregnancy is not indicated; if exposure occurs, evaluate for potential anomalies. |
■ FDA Black Box Warning
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptives. This risk increases with age (especially in women >35 years) and with the number of cigarettes smoked. Women who use combination oral contraceptives should be strongly advised not to smoke.
| Serious Effects |
["Current or past thrombophlebitis, thromboembolic disorders, or cerebrovascular disease","Known or suspected pregnancy","Undiagnosed abnormal genital bleeding","Known or suspected breast cancer or other estrogen/progestin-sensitive neoplasms","Hepatic tumors (benign or malignant) or active liver disease","Heavy smoking (>15 cigarettes/day) in women aged ≥35 years"]
| Precautions | ["Thrombotic disorders (e.g., DVT, PE, MI, stroke): discontinue if symptoms occur","Hepatic disease: discontinue if jaundice or impaired liver function","Hypertension: monitor blood pressure, discontinue if uncontrolled","Gallbladder disease: increased risk of cholecystitis and cholelithiasis","Carbohydrate metabolism: monitor glucose in diabetic patients","Headache: evaluate for migraine or cerebrovascular ischemia","Uterine bleeding: rule out pregnancy or malignancy","Depression: discontinue if severe or recurrent","Ocular effects: discontinue if papilledema or retinal vascular lesions","Drug interactions: reduced contraceptive efficacy with CYP3A4 inducers (e.g., rifampin, anticonvulsants, St. John's wort)"] |
Loading safety data…
| Fetal Monitoring | Monitor for signs of thromboembolism (leg pain/swelling, chest pain, dyspnea), hypertension (blood pressure checks at each visit), and hepatic function (ALT, AST) if symptoms occur. In pregnancy rule out via urine beta-hCG before initiating. No specific fetal monitoring required if used inadvertently; ultrasound to assess fetal anatomy if exposure occurs. |
| Fertility Effects | Tri-Mili suppresses ovulation via inhibition of gonadotropins; fertility returns to baseline within 1-3 months after discontinuation. No evidence of long-term impairment of fertility. Use does not cause infertility. |